Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 33 of the 112 sources its claims cite were checked for support.

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives

Open access

Abstract

Background/Objectives: Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with KRAS mutations occurring in 30–40% of cases, contributing to poor prognosis and resistance to anti-EGFR therapy. This review explores the biological significance, clinical implications, and therapeutic targeting of KRAS mutations in CRC. Methods: A comprehensive analysis of the existing literature and clinical trials was performed, highlighting the role of KRAS mutations in CRC pathogenesis, their impact on prognosis, and recent advancements in targeted therapies. Specific attention was given to emerging therapeutic strategies and resistance mechanisms. Results: KRAS mutations drive tumor progression through persistent activation of MAPK/ERK and PI3K/AKT signaling pathways. These mutations influence the tumor microenvironment, cancer stem cell formation, macropinocytosis, and cell competition. KRAS-mutant CRC exhibits poor responsiveness to anti-EGFR monoclonal antibodies and demonstrates primary and acquired resistance to KRAS inhibitors. Recent breakthroughs include the development of KRAS G12C inhibitors (sotorasib and adagrasib) and promising agents targeting G12D mutations. However, response rates in CRC remain suboptimal compared to other cancers, necessitating combination therapies and novel approaches, such as vaccines, nucleic acid-based therapeutics, and macropinocytosis inhibitors. Conclusions: KRAS mutations are central to CRC pathogenesis and present a significant therapeutic challenge. Advances in KRAS-targeted therapies offer hope for improved outcomes, but resistance mechanisms and organ-specific differences limit efficacy. Continued efforts in personalized treatment strategies and translational research are critical for overcoming these challenges and improving patient survival.

Overview

CoChat Summary

TL;DR

KRAS mutations occur in roughly 30–40% of colorectal cancers and drive MAPK/ERK and PI3K/AKT signaling, poor prognosis, and resistance to anti-EGFR antibodies. Although KRASG12C inhibitors such as sotorasib and adagrasib are breakthroughs, their efficacy in colorectal cancer remains limited, so combination therapies, G12D/G12X/SOS1 inhibitors, vaccines, peptides, and nucleic acid therapeutics are under development.

Key findings

  • KRAS mutations are found in 30–40% of colorectal cancer cases and are associated with persistent activation of MAPK/ERK and PI3K/AKT pathways, poor prognosis, and resistance to anti-EGFR monoclonal antibodies such as panitumumab and cetuximab.
  • In colorectal cancer, KRASG12C inhibitors have an overall response rate of only around 10%; KRASG12C mutations occur in only 3–4% of colorectal cancer cases, whereas G12D is found in 28% of colorectal cancers and 39% of pancreatic cancers.
  • Sotorasib showed a 33.3% response rate, 57.9% stable disease rate, and 91.2% disease control rate in non-small cell lung cancer; adagrasib showed a 42.9% response rate. In KRASG12C-mutant colorectal cancer, combination KRASG12C plus EGFR inhibition produced a 43% response rate (12/28 patients) versus 22% (10/45 patients) with KRASG12C inhibitor monotherapy.
  • RAS-mutant colorectal cancer patients continue to have poor outcomes, with overall survival remaining at 15–17 months despite advances in systemic therapy.

Methods

  • This is a narrative review, not an original research study; it synthesizes prior biological, clinical, and therapeutic literature on KRAS-mutant colorectal cancer.
  • No primary sample, dataset, or statistical analysis is reported; the paper draws on cited clinical trials, preclinical studies, and mechanistic reports.
  • The review covers KRAS biology, clinical testing, resistance mechanisms, and emerging therapeutic strategies including small-molecule inhibitors, peptides, vaccines, metabolic targeting, and oligonucleotide therapeutics.

Limitations

  • Stated in the paper: RAS mutation testing cannot achieve 100% accuracy because of testing method sensitivity, sample quality, and tumor cell content; there are no guidelines defining the threshold level of mutant RAS that impacts treatment efficacy, and it remains unclear which RAS mutant types have the highest clinical utility.
  • Stated in the paper: resistance to KRAS-targeted therapy is common, with primary and acquired resistance mechanisms including feedback pathway activation, KRAS independence, organ-specific sensitivity, EMT, secondary mutations, and bypass signaling.
  • Evident from the text: as a narrative review, it does not describe a systematic search strategy, risk-of-bias assessment, or meta-analysis, and it presents no original patient-level data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers17030428

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Activation states of KRAS and their impact on signaling pathways. This schematic illustrates the activation cycle of KRAS, highlighting its transition between the inactive GDP-bound state (“KRAS OFF”) and the active GTP-bound state (“KRAS ON”). In the GDP-bound state, KRAS remains inactive, with no downstream signaling. Upon receptor tyrosine kinase (RTK) activation, guanine nucleotide exchange factors (GEFs) facilitate the exchange of GDP for GTP, activating KRAS. Active KRAS (GTP-bound) initiates multiple downstream signaling pathways, including the MAPK and PI3K-AKT cascades, driving cell proliferation. GTPase-activating proteins (GAPs) subsequently inactivate KRAS by hydrolyzing GTP back to GDP. Additionally, Arf6-mediated mechanisms in KRAS regulation are depicted. This diagram emphasizes the functional significance of KRAS’s activation states in regulating cellular signaling and proliferation.
Figure 1 Activation states of KRAS and their impact on signaling pathways. This schematic illustrates the activation cycle of KRAS, highlighting its transition between the inactive GDP-bound state (“KRAS OFF”) and the active GTP-bound state (“KRAS ON”). In the GDP-bound state, KRAS remains inactive, with no downstream signaling. Upon receptor tyrosine kinase (RTK) activation, guanine nucleotide exchange factors (GEFs) facilitate the exchange of GDP for GTP, activating KRAS. Active KRAS (GTP-bound) initiates multiple downstream signaling pathways, including the MAPK and PI3K-AKT cascades, driving cell proliferation. GTPase-activating proteins (GAPs) subsequently inactivate KRAS by hydrolyzing GTP back to GDP. Additionally, Arf6-mediated mechanisms in KRAS regulation are depicted. This diagram emphasizes the functional significance of KRAS’s activation states in regulating cellular signaling and proliferation.CC BY · PubMed Central
Figure 2 Evolution of chemotherapy and survival rates in unresectable advanced and recurrent colorectal cancer. Light gray represents cases with wild-type KRAS, while dark gray (*) indicates cases with KRAS mutations. Due to differences in time periods and study backgrounds, direct comparisons of survival rates are not feasible.
Figure 2 Evolution of chemotherapy and survival rates in unresectable advanced and recurrent colorectal cancer. Light gray represents cases with wild-type KRAS, while dark gray (*) indicates cases with KRAS mutations. Due to differences in time periods and study backgrounds, direct comparisons of survival rates are not feasible.CC BY · PubMed Central
Figure 3 KRAS mutation rates across various cancer types and corresponding targeted therapies. The upper figure depicts the proportion (%) of KRAS codons across various cancer types, while the lower figure highlights the types of targeted therapies currently available for each codon. CRC (colorectal cancer), NSCLC (non-small cell lung cancer), EAC (esophageal adenocarcinoma), CC (cholangiocarcinoma), GC (gastric cancer), PDAC (pancreatic ductal adenocarcinoma).
Figure 3 KRAS mutation rates across various cancer types and corresponding targeted therapies. The upper figure depicts the proportion (%) of KRAS codons across various cancer types, while the lower figure highlights the types of targeted therapies currently available for each codon. CRC (colorectal cancer), NSCLC (non-small cell lung cancer), EAC (esophageal adenocarcinoma), CC (cholangiocarcinoma), GC (gastric cancer), PDAC (pancreatic ductal adenocarcinoma).CC BY · PubMed Central
Figure 4 The resistance mechanism in colorectal cancer during KRAS inhibition. This model depicts the key resistance mechanisms. This figure also highlights pathway crosstalk, including the role of metabolic reprogramming and the activation of compensatory signaling nodes (e.g., YAP/TEAD and NRF2).
Figure 4 The resistance mechanism in colorectal cancer during KRAS inhibition. This model depicts the key resistance mechanisms. This figure also highlights pathway crosstalk, including the role of metabolic reprogramming and the activation of compensatory signaling nodes (e.g., YAP/TEAD and NRF2).CC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 4 Not valid · 55 Not checked · 28 Own results and interpretations

57 more claims · 14 with their cited sources checked

Create a free account to see all 107 claims and to verify the 79 references still open.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 84 references

Cited by

See all 83

Metadata

Authors
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., Doki, Y., & Eguchi, H.
Affiliations
The University of Osaka (JP)
Corresponding author
Takeda, Mitsunobu
Venue
Cancers
Publisher
MDPI AG
Published
2025-01-27
Volume
17
Issue
3
Pages
428
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4406867792
Cited by
82
References
84
Citations by year
2026: 52 · 2025: 30
FWCI
9.59
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (23K08128)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS mutation, colorectal cancer, ERK signaling, PI3K/Akt signaling, tumor microenvironment, cancer stem cells, macropinocytosis, cell competition, anti-EGFR therapy resistance, KRAS inhibitors, KRAS G12C inhibitors, sotorasib, adagrasib, KRAS G12D, combination therapy, cancer vaccines, nucleic acid therapeutics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. https://app.cochat.ai/papers/10.3390/cancers17030428
The paper
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., Doki, Y., & Eguchi, H. (2025). The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. Cancers. https://doi.org/10.3390/cancers17030428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.